We are live on
!
Find out more
SM
Sabby Management Portfolio holdings
AUM
$111M
1-Year Est. Return
74.4%
This Fund
S&P 500
This Quarter
Est. Return
+15.75%
1 Year Est. Return
-74.4%
3 Year Est. Return
-95.55%
5 Year Est. Return
-99.44%
10 Year Est. Return
-99.5%
AUM
$1.54B
AUM Growth
+$40.4M
(+2.7%)
Cap. Flow
-$19.3M
Cap. Flow
% of AUM
-1.25%
Top 10 Holdings %
Top 10 Hldgs %
46.87%
Holding
259
New
90
Increased
52
Reduced
41
Closed
65
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vertex Pharmaceuticals
VRTX
|
+$25.6M |
| 2 |
Tompkins Financial
TMP
|
+$13.1M |
| 3 |
AGEN
Agenus
AGEN
|
+$6.13M |
| 4 |
MannKind Corp
MNKD
|
+$5.33M |
| 5 |
MDVN
MEDIVATION, INC.
MDVN
|
+$3.71M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AEGR
Aegerion Pharmaceuticals
AEGR
|
+$28.4M |
| 2 |
AbbVie
ABBV
|
+$14.7M |
| 3 |
Zoetis
ZTS
|
+$14.2M |
| 4 |
iShares 20+ Year Treasury Bond ETF
TLT
|
+$11.5M |
| 5 |
Arrowhead Research
ARWR
|
+$8.75M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 89.38% |
| 2 | Healthcare | 10.49% |
| 3 | Financials | 0.07% |
| 4 | Technology | 0.07% |
| 5 | Energy | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
HOLX
76
CALL
DELISTED
Hologic
HOLX
| $2.29M | 0.15% |
+1,110
| New | +$23.6K |
|
77
PUT
Acadia Pharmaceuticals
ACAD
$4.74B
| $2.29M | 0.15% |
+833
| New | +$17.4K |
|
78
PUT
Insmed
INSM
$28.3B
| $2.25M | 0.15% |
+1,440
| New | +$18.3K |
|
|
PCYC
79
PUT
DELISTED
PHARMACYCLICS INC
PCYC
| $2.15M | 0.14% |
+155
| New | +$17.2K |
|
|
SZYM
80
DELISTED
SOLAZYME INC COM STK (DE)
SZYM
| $2.14M | 0.14% |
+198,350
| New | +$2.26M |
|
|
SZYM
81
PUT
DELISTED
SOLAZYME INC COM STK (DE)
SZYM
| $2.12M | 0.14% |
1,964
+421
| +27% | +$4.79K |
|
|
CASI
82
DELISTED
CASI Pharmaceuticals
CASI
| $2.06M | 0.13% |
117,896
+637
| +0.5% | +$12.1K |
|
83
PUT
Eli Lilly
LLY
$1.01T
| $2.05M | 0.13% |
407
| – | – |
|
|
XOMA
84
DELISTED
Xoma
XOMA
| $2.04M | 0.13% |
+22,784
| New | +$2.07M |
|
|
MDCO
85
CALL
DELISTED
Medicines Co
MDCO
| $2.03M | 0.13% |
+605
| New | +$19.3K |
|
86
CALL
Vanda Pharmaceuticals
VNDA
$311M
| $2M | 0.13% |
+1,827
| New | +$19.5K |
|
|
AMRN
87
PUT
Amarin Corp
AMRN
$291M
| $1.95M | 0.13% |
154
-184
| -54% | -$22K |
|
88
PUT
Madrigal Pharmaceuticals
MDGL
$12.3B
| $1.89M | 0.12% |
85
+23
| +37% | +$4.89K |
|
|
RXII
89
PUT
DELISTED
GALENA BIOPHARMA INC COM
RXII
| $1.81M | 0.12% |
7,990
+6,699
| +519% | +$1.52M |
|
|
UNXL
90
PUT
DELISTED
Uni-Pixel, Inc.
UNXL
| $1.77M | 0.12% |
998
+406
| +69% | +$6.47K |
|
|
ELN
91
CALL
DELISTED
ELAN CORP ADS(RP1 ORD4IRISH PN
ELN
| $1.71M | 0.11% |
1,100
-7,229
| -87% | -$109K |
|
|
CEMP
92
DELISTED
Cempra, Inc.
CEMP
| $1.71M | 0.11% |
148,572
-1,428
| -1% | -$12.5K |
|
|
PCYC
93
DELISTED
PHARMACYCLICS INC
PCYC
| $1.71M | 0.11% |
+12,350
| New | +$1.37M |
|
|
94
Eli Lilly
LLY
$1.01T
| $1.67M | 0.11% |
33,156
+14,934
| +82% | +$782K |
|
|
95
PUT
Vanda Pharmaceuticals
VNDA
$311M
| $1.66M | 0.11% |
+1,515
| New | +$16.2K |
|
96
CALL
Incyte
INCY
$24.8B
| $1.64M | 0.11% |
431
| – | – |
|
97
Tempest Therapeutics
TPST
$13M
| $1.6M | 0.1% |
+55
| New | +$1.95M |
|
|
ARIA
98
CALL
DELISTED
Ariad Pharmaceuticals Inc
ARIA
| $1.6M | 0.1% |
870
+576
| +196% | +$11.2K |
|
99
Savara
SVRA
$1.09B
| $1.6M | 0.1% |
51,994
-58,176
| -53% | -$1.81M |
|
100
Talphera
TLPH
$64.4M
| $1.59M | 0.1% |
+7,404
| New | +$1.62M |
|
Similar funds
IWA
BFA
WPWM
BCM
ZS
KC
FI
CIM
Sabby Management's Q3 2013 Portfolio in Review
As of Q3 2013, Sabby Management held 259 positions worth $1.54B, up 2.7% from $1.5B the previous quarter. Its ten largest holdings account for 47% of the portfolio.
Sabby Management's Q3 2013 filing shows 90 new, 52 increased, 41 reduced and 65 closed positions. Its largest new stake was Tompkins Financial: 288,454 shares worth $1.02M. The largest sale was Aegerion Pharmaceuticals, an estimated $28.4M.
By sector, the portfolio is most concentrated in Miscellaneous at 89% of assets, up from 89% a quarter earlier, followed by Healthcare and Financials.
- Sabby Management's largest Q3 2013 buy was Tompkins Financial: 288,454 shares worth $1.02M.
- Sabby Management added most to Vertex Pharmaceuticals in Q3 2013, an estimated $25.6M increase.
- Sabby Management's biggest Q3 2013 reduction was Aegerion Pharmaceuticals, cutting an estimated $28.4M.
- Sabby Management fully exited AbbVie in Q3 2013, selling an estimated $14.7M.
- Sabby Management's ten largest holdings make up 47% of its $1.54B portfolio in Q3 2013.
- Sabby Management opened 90 new positions and closed 65 in Q3 2013.
- Sabby Management's portfolio value rose 2.7% quarter-over-quarter to $1.54B.
Based on Sabby Management's 13F filing for Q3 2013, filed 14 Nov 2013.